Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:7681514rdf:typepubmed:Citationlld:pubmed
pubmed-article:7681514lifeskim:mentionsumls-concept:C0034721lld:lifeskim
pubmed-article:7681514lifeskim:mentionsumls-concept:C0034693lld:lifeskim
pubmed-article:7681514lifeskim:mentionsumls-concept:C1522318lld:lifeskim
pubmed-article:7681514lifeskim:mentionsumls-concept:C1282822lld:lifeskim
pubmed-article:7681514lifeskim:mentionsumls-concept:C0226001lld:lifeskim
pubmed-article:7681514lifeskim:mentionsumls-concept:C0028066lld:lifeskim
pubmed-article:7681514lifeskim:mentionsumls-concept:C0028116lld:lifeskim
pubmed-article:7681514lifeskim:mentionsumls-concept:C0205409lld:lifeskim
pubmed-article:7681514lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:7681514lifeskim:mentionsumls-concept:C1533691lld:lifeskim
pubmed-article:7681514lifeskim:mentionsumls-concept:C0064568lld:lifeskim
pubmed-article:7681514pubmed:issue3lld:pubmed
pubmed-article:7681514pubmed:dateCreated1993-4-29lld:pubmed
pubmed-article:7681514pubmed:abstractTextWe investigated the effect of 1,4-dihydropyridine calcium antagonists (nifedipine, nisoldipine, and lacidipine) on serotonin (5-HT)- and KCl (120 mM)-induced contractions of rat isolated septal coronary artery. The preparations showed the well-known biphasic response to KCl depolarization. All three calcium antagonists were more potent in inhibiting the second, tonic phase compared to the first, transient phase, with pIC50 values of 7.17 +/- 0.12/8.27 +/- 0.07 (nifedipine), 7.93 +/- 0.21/8.96 +/- 0.06 (nisoldipine), and 8.28 +/- 0.07/9.79 +/- 0.04 (lacidipine) for suppressing the first and the second phase, respectively. Furthermore, the influence of the calcium antagonists on the 5-HT concentration-response curve was investigated. Nifedipine, nisoldipine, and lacidipine concentration dependently depressed the maximum effect of 5-HT on the coronary artery preparations without influencing the pEC50 of the 5-HT concentration-response curve. In conclusion, all three dihydropyridine calcium antagonists are potent and effective inhibitors of depolarization- or 5-HT-induced coronary artery contractions. Lacidipine, a new lipophilic compound, was the most potent one in inhibiting the depolarization-induced contraction, thereby showing a marked selectivity for the tonic phase compared to the initial phasic response.lld:pubmed
pubmed-article:7681514pubmed:languageenglld:pubmed
pubmed-article:7681514pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7681514pubmed:citationSubsetIMlld:pubmed
pubmed-article:7681514pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7681514pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7681514pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7681514pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7681514pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7681514pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7681514pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7681514pubmed:statusMEDLINElld:pubmed
pubmed-article:7681514pubmed:monthMarlld:pubmed
pubmed-article:7681514pubmed:issn0160-2446lld:pubmed
pubmed-article:7681514pubmed:authorpubmed-author:van...lld:pubmed
pubmed-article:7681514pubmed:authorpubmed-author:MathyM JMJlld:pubmed
pubmed-article:7681514pubmed:authorpubmed-author:PfaffendorfMMlld:pubmed
pubmed-article:7681514pubmed:issnTypePrintlld:pubmed
pubmed-article:7681514pubmed:volume21lld:pubmed
pubmed-article:7681514pubmed:ownerNLMlld:pubmed
pubmed-article:7681514pubmed:authorsCompleteYlld:pubmed
pubmed-article:7681514pubmed:pagination496-502lld:pubmed
pubmed-article:7681514pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:7681514pubmed:meshHeadingpubmed-meshheading:7681514-...lld:pubmed
pubmed-article:7681514pubmed:meshHeadingpubmed-meshheading:7681514-...lld:pubmed
pubmed-article:7681514pubmed:meshHeadingpubmed-meshheading:7681514-...lld:pubmed
pubmed-article:7681514pubmed:meshHeadingpubmed-meshheading:7681514-...lld:pubmed
pubmed-article:7681514pubmed:meshHeadingpubmed-meshheading:7681514-...lld:pubmed
pubmed-article:7681514pubmed:meshHeadingpubmed-meshheading:7681514-...lld:pubmed
pubmed-article:7681514pubmed:meshHeadingpubmed-meshheading:7681514-...lld:pubmed
pubmed-article:7681514pubmed:meshHeadingpubmed-meshheading:7681514-...lld:pubmed
pubmed-article:7681514pubmed:meshHeadingpubmed-meshheading:7681514-...lld:pubmed
pubmed-article:7681514pubmed:meshHeadingpubmed-meshheading:7681514-...lld:pubmed
pubmed-article:7681514pubmed:meshHeadingpubmed-meshheading:7681514-...lld:pubmed
pubmed-article:7681514pubmed:meshHeadingpubmed-meshheading:7681514-...lld:pubmed
pubmed-article:7681514pubmed:meshHeadingpubmed-meshheading:7681514-...lld:pubmed
pubmed-article:7681514pubmed:year1993lld:pubmed
pubmed-article:7681514pubmed:articleTitleIn vitro effects of nifedipine, nisoldipine, and lacidipine on rat isolated coronary small arteries.lld:pubmed
pubmed-article:7681514pubmed:affiliationDepartment of Pharmacotherapy, University of Amsterdam, The Netherlands.lld:pubmed
pubmed-article:7681514pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:7681514pubmed:publicationTypeIn Vitrolld:pubmed